By Sharon M. Albright, DVM, CCRT
Golden retriever Holleigh recently participated in a clinical trial conducted through the Comparative Brain Tumor Consortium exploring an oral blood-brain barrier penetrant—procaspase-3 activator (PAC-1)—in combination with hydroxyurea for treatment of canine meningioma. She is pictured here with her owners, Travis and Casie Smith.
The path to discover and perfect new cancer treatments is long and expensive. It can take more than a decade and cost over $2 billion to demonstrate the safety and efficacy of a new therapeutic before it reaches the marketplace. To expedite the process, researchers are thinking outside the box—or rather, outside their own species. The concept of comparative medicine (i.e. One Medicine) has great potential to a...
You’ve landed on a members-only feature.
If you are already a member, please log in below.
Join VPN Plus+ today to get access to this feature and more like:
- Members-only content:
- In-depth case studies
- New protocols
- Detailed practice management strategies
- More from some of your favorite columnists like Patty Khuly and Brennen McKenzie
- Exclusive webinars, roundtables and videos
- And additional benefits including:
- VIP discounts to VetMedTeam online education and VetCE events
- An annual ‘Vet Box’ full of curated products just for you!